Please use this identifier to cite or link to this item:
Title: Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study
Author: Garcia Vidal, Carolina
Sanjuan, Gemma
Moreno García, Estela
Puerta Alcalde, Pedro
Garcia-Pouton, Nicole
Chumbita, Mariana
Fernández Pittol, Mariana José
Pitart, Cristina
Inciarte Portillo, Alexy
Bodro, Marta
Morata, Laura
Ambrosioni, Juan
Grafia, Ignacio
Meira, Fernanda
Macaya, Irene
Cardozo Espinola, Celia
Casals Pascual, Climent
Tellez, Adrian
Castro Rebollo, Pedro
Marco Reverté, Francesc
García Alcaide, Felipe
Mensa Pueyo, Josep
Martínez, José Antonio (Martínez Martínez)
Soriano Viladomiu, Alex
COVID-19 Researchers Group
Keywords: COVID-19
Issue Date: 31-Jul-2020
Publisher: European Society of Clinical Microbiology and Infectious Diseases
Abstract: Objectives: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19). Methods: We performed an observational cohort study of all consecutive patients admitted for ≥48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records. Results: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes. Conclusions: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies.
Note: Versió postprint del document publicat a:
It is part of: Clinical Microbiology and Infection, 2020, vol. S1198-743X
Related resource:
ISSN: 1198-743X
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
704106.pdf481.85 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.